Effects Of Combination With Parathyroid And β-blocker On The Proliferation, Osteoprotegin And Receptor Activator Of NF-κB Ligand Gene Expression In Human Osteoblasts

Objective:To explore the effect and possible mechanism of combination with rhPTH1-34and propranolol on the proliferation, OPG and RANKL gene expression in human osteoblasts in vitro. We hope to provide experimental basis for new therapeutic methods of osteoporosis.Methods:First, human trabecular bone specimen of ilium and femoral neck from adult patients were obtained, and primary human osteoblasts were isolated, cultured and identified. Second, human osteoblasts were used as an in vitro model, which were respectively and combinedly treated with rhPTHl-34in fixed concentration(50ng/ml)and propranolol in different concentrations(0.1uM,1uM,10uM) after72h. Cell proliferation was assessed by CCK-8and the expression of OPG and RANKL mRNA were analyzed by real time quantitative PCR.Results:PTH1-34and PRO monotherapy can promote osteoblast proliferation(P<0.05), and the expression of OPG mRNA was increased as the PRO concentration of10uM((P<0.05), which is more than the expression of RANKL mRNA; rather, combined treatment of rhPTH1-34and PRO can inhibit cell proliferation and the expression of OPG and RANKL mRNA(P<0.05).Conclusion:PTH1-34and PRO monotherapy can promote osteoblast proliferation, but the combined treatment group can inhibit osteoblast proliferation, which may achieve it through regulating the expression of OPG and RANKL.